Janssen Seeks Darzalex Approval for Certain Newly Diagnosed Multiple Myeloma Patients in Japan
Janssen Pharmaceutical has submitted an application to Japanese authorities requesting…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Split Dosing Regimen of Darzalex Approved in Europe for Multiple Myeloma Patients
The European Commission has approved a new dosing regimen…
Aplidin Approved in Australia for Relapsed or Refractory Multiple Myeloma
Treatment with Aplidin (plitidepsin) in combination with…
Triple Combo Therapy May Slow Smoldering Multiple Myeloma Progression into Overt Myeloma, Phase 2 Trial Shows
Early treatment with a triple combination therapy containing Empliciti…
Nonprofit Launches Trial to Get Therapies to Multiple Myeloma Patients More Efficiently
The Multiple Myeloma Research Foundation (MMRF) is launching…
Phase 2 Myeloma Trial for Investigational CAR T-cell Therapy bb2121 Completes Enrollment
An international Phase 2 trial testing the investigational CAR…
